Global Viral Vector Manufacturing
Global Viral Vector Manufacturing

Viral Vector Manufacturing Comprehensive Study by Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno-associated viruses, Plant viruses, Hybrids, Others), Application (Research, Gene Therapy, Vaccines, Medicine Delivery, Other), End User (Pharmaceuticals, Research Institutes, Hospitals, Others) Players and Region - Global Market Outlook to 2026

Viral Vector Manufacturing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 233 Pages 183 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Viral vectors are technologies that are used to transmit genetic information into cells. In gene therapy, modified viruses are utilized as viral vectors to safeguard the new gene while delivering it to the gene cassette in target cells. Due to genetic engineering, the majority of critical genes in viral vectors are missing, hence viral vectors are frequently produced in culture using specific cells that provide the necessary viral proteins needed to properly package the therapeutic gene into virus particles. Viral vector manufacturing is a new field and high research is going on in the field. It is used in gene therapy and vaccine making. North America is the largest market for Viral Vector Manufacturing followed by Europe and the Asia Pacific.This growth is primarily driven by Need Of Viral Vector Manufacturing in Gene Therapy and Demand Of Viral Vectors in Vaccinology.

Globally, a noticeable market trend is evident Adoption Of New Techniques in Viral Vector Production Workflow. The Biotechnology sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Thermo Fisher Scientific (United States), Vibalogics (United States), Lonza (Switzerland), Merck (Germany), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (United States), Spark Therapeutics (United States), Oxford BioMedica (United Kingdom), CGT Catapult (United Kingdom) and Cobra Biologics (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 15th Jan 2021, Thermo Fisher Scientific Inc., the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading provider of services and technologies for the life sciences industry, announced that Thermo Fisher has completed the acquisition of Novasep's viral vector manufacturing business in Belgium, Henogen S.A., for approximately 725 million in cash. Novasep's viral vector production division provides biotechnology and major biopharma customers with contract manufacturing services for vaccines and medicines.


Market Drivers
  • Need Of Viral Vector Manufacturing in Gene Therapy
  • Demand Of Viral Vectors in Vaccinology

Market Trend
  • Adoption Of New Techniques in Viral Vector Production Workflow

Restraints
  • Talent Shortage in Viral Vector Manufacturing Market

Opportunities
Covid-19 Pandemic Has Drastically Increased the Demand of Viral Vector Vaccines and Growing Investment in Medical Research Will Boost the Demand of Viral Vector Manufacturing
Challenges
Complex Nature of Viral Vector Manufacturing and Different Regulations About Viral Vector Manufacturing in Different Regions

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Viral Vector Manufacturing Study Sheds Light on
— The Viral Vector Manufacturing Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Viral Vector Manufacturing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Viral Vector Manufacturing industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Viral Vector Manufacturing Market?
The Viral Vector Manufacturing market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Viral Vector Manufacturing Market?
Top performing companies in the Global Viral Vector Manufacturing market are Thermo Fisher Scientific (United States), Vibalogics (United States), Lonza (Switzerland), Merck (Germany), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (United States), Spark Therapeutics (United States), Oxford BioMedica (United Kingdom), CGT Catapult (United Kingdom) and Cobra Biologics (United Kingdom), to name a few.

3. Which region dominated the worldwide market for Viral Vector Manufacturing in 2020?
North America is dominating the Viral Vector Manufacturing Market.
Report Objectives / Segmentation Covered
By Type
  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno-associated viruses
  • Plant viruses
  • Hybrids
  • Others
By Application
  • Research
  • Gene Therapy
  • Vaccines
  • Medicine Delivery
  • Other
By End User
  • Pharmaceuticals
  • Research Institutes
  • Hospitals
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need Of Viral Vector Manufacturing in Gene Therapy
      • 3.2.2. Demand Of Viral Vectors in Vaccinology
    • 3.3. Market Challenges
      • 3.3.1. Complex Nature of Viral Vector Manufacturing
      • 3.3.2. Different Regulations About Viral Vector Manufacturing in Different Regions
    • 3.4. Market Trends
      • 3.4.1. Adoption Of New Techniques in Viral Vector Production Workflow
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Vector Manufacturing, by Type, Application, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Viral Vector Manufacturing (Value)
      • 5.2.1. Global Viral Vector Manufacturing by: Type (Value)
        • 5.2.1.1. Retroviruses
        • 5.2.1.2. Lentiviruses
        • 5.2.1.3. Adenoviruses
        • 5.2.1.4. Adeno-associated viruses
        • 5.2.1.5. Plant viruses
        • 5.2.1.6. Hybrids
        • 5.2.1.7. Others
      • 5.2.2. Global Viral Vector Manufacturing by: Application (Value)
        • 5.2.2.1. Research
        • 5.2.2.2. Gene Therapy
        • 5.2.2.3. Vaccines
        • 5.2.2.4. Medicine Delivery
        • 5.2.2.5. Other
      • 5.2.3. Global Viral Vector Manufacturing by: End User (Value)
        • 5.2.3.1. Pharmaceuticals
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Hospitals
        • 5.2.3.4. Others
      • 5.2.4. Global Viral Vector Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Viral Vector Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Vibalogics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. UniQure (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. FUJIFILM Diosynth Biotechnologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Spark Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oxford BioMedica (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CGT Catapult (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cobra Biologics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Viral Vector Manufacturing Sale, by Type, Application, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Viral Vector Manufacturing (Value)
      • 7.2.1. Global Viral Vector Manufacturing by: Type (Value)
        • 7.2.1.1. Retroviruses
        • 7.2.1.2. Lentiviruses
        • 7.2.1.3. Adenoviruses
        • 7.2.1.4. Adeno-associated viruses
        • 7.2.1.5. Plant viruses
        • 7.2.1.6. Hybrids
        • 7.2.1.7. Others
      • 7.2.2. Global Viral Vector Manufacturing by: Application (Value)
        • 7.2.2.1. Research
        • 7.2.2.2. Gene Therapy
        • 7.2.2.3. Vaccines
        • 7.2.2.4. Medicine Delivery
        • 7.2.2.5. Other
      • 7.2.3. Global Viral Vector Manufacturing by: End User (Value)
        • 7.2.3.1. Pharmaceuticals
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Hospitals
        • 7.2.3.4. Others
      • 7.2.4. Global Viral Vector Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Vector Manufacturing: by Type(USD Million)
  • Table 2. Viral Vector Manufacturing Retroviruses , by Region USD Million (2015-2020)
  • Table 3. Viral Vector Manufacturing Lentiviruses , by Region USD Million (2015-2020)
  • Table 4. Viral Vector Manufacturing Adenoviruses , by Region USD Million (2015-2020)
  • Table 5. Viral Vector Manufacturing Adeno-associated viruses , by Region USD Million (2015-2020)
  • Table 6. Viral Vector Manufacturing Plant viruses , by Region USD Million (2015-2020)
  • Table 7. Viral Vector Manufacturing Hybrids , by Region USD Million (2015-2020)
  • Table 8. Viral Vector Manufacturing Others , by Region USD Million (2015-2020)
  • Table 9. Viral Vector Manufacturing: by Application(USD Million)
  • Table 10. Viral Vector Manufacturing Research , by Region USD Million (2015-2020)
  • Table 11. Viral Vector Manufacturing Gene Therapy , by Region USD Million (2015-2020)
  • Table 12. Viral Vector Manufacturing Vaccines , by Region USD Million (2015-2020)
  • Table 13. Viral Vector Manufacturing Medicine Delivery , by Region USD Million (2015-2020)
  • Table 14. Viral Vector Manufacturing Other , by Region USD Million (2015-2020)
  • Table 15. Viral Vector Manufacturing: by End User(USD Million)
  • Table 16. Viral Vector Manufacturing Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 17. Viral Vector Manufacturing Research Institutes , by Region USD Million (2015-2020)
  • Table 18. Viral Vector Manufacturing Hospitals , by Region USD Million (2015-2020)
  • Table 19. Viral Vector Manufacturing Others , by Region USD Million (2015-2020)
  • Table 20. South America Viral Vector Manufacturing, by Country USD Million (2015-2020)
  • Table 21. South America Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 22. South America Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 23. South America Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 24. Brazil Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 25. Brazil Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 26. Brazil Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 27. Argentina Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 28. Argentina Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 29. Argentina Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 30. Rest of South America Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 33. Asia Pacific Viral Vector Manufacturing, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 36. Asia Pacific Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 37. China Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 38. China Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 39. China Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 40. Japan Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 41. Japan Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 42. Japan Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 43. India Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 44. India Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 45. India Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 46. South Korea Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 47. South Korea Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 48. South Korea Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 49. Taiwan Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 50. Taiwan Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 51. Taiwan Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 52. Australia Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 53. Australia Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 54. Australia Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 58. Europe Viral Vector Manufacturing, by Country USD Million (2015-2020)
  • Table 59. Europe Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 60. Europe Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 61. Europe Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 62. Germany Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 63. Germany Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 64. Germany Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 65. France Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 66. France Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 67. France Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 68. Italy Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 69. Italy Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 70. Italy Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 71. United Kingdom Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 72. United Kingdom Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 73. United Kingdom Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 74. Netherlands Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 75. Netherlands Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 76. Netherlands Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 77. Rest of Europe Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 78. Rest of Europe Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 79. Rest of Europe Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 80. MEA Viral Vector Manufacturing, by Country USD Million (2015-2020)
  • Table 81. MEA Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 82. MEA Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 83. MEA Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 84. Middle East Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 85. Middle East Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 86. Middle East Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 87. Africa Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 88. Africa Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 89. Africa Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 90. North America Viral Vector Manufacturing, by Country USD Million (2015-2020)
  • Table 91. North America Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 92. North America Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 93. North America Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 94. United States Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 95. United States Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 96. United States Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 97. Canada Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 98. Canada Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 99. Canada Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 100. Mexico Viral Vector Manufacturing, by Type USD Million (2015-2020)
  • Table 101. Mexico Viral Vector Manufacturing, by Application USD Million (2015-2020)
  • Table 102. Mexico Viral Vector Manufacturing, by End User USD Million (2015-2020)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Viral Vector Manufacturing: by Type(USD Million)
  • Table 114. Viral Vector Manufacturing Retroviruses , by Region USD Million (2021-2026)
  • Table 115. Viral Vector Manufacturing Lentiviruses , by Region USD Million (2021-2026)
  • Table 116. Viral Vector Manufacturing Adenoviruses , by Region USD Million (2021-2026)
  • Table 117. Viral Vector Manufacturing Adeno-associated viruses , by Region USD Million (2021-2026)
  • Table 118. Viral Vector Manufacturing Plant viruses , by Region USD Million (2021-2026)
  • Table 119. Viral Vector Manufacturing Hybrids , by Region USD Million (2021-2026)
  • Table 120. Viral Vector Manufacturing Others , by Region USD Million (2021-2026)
  • Table 121. Viral Vector Manufacturing: by Application(USD Million)
  • Table 122. Viral Vector Manufacturing Research , by Region USD Million (2021-2026)
  • Table 123. Viral Vector Manufacturing Gene Therapy , by Region USD Million (2021-2026)
  • Table 124. Viral Vector Manufacturing Vaccines , by Region USD Million (2021-2026)
  • Table 125. Viral Vector Manufacturing Medicine Delivery , by Region USD Million (2021-2026)
  • Table 126. Viral Vector Manufacturing Other , by Region USD Million (2021-2026)
  • Table 127. Viral Vector Manufacturing: by End User(USD Million)
  • Table 128. Viral Vector Manufacturing Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 129. Viral Vector Manufacturing Research Institutes , by Region USD Million (2021-2026)
  • Table 130. Viral Vector Manufacturing Hospitals , by Region USD Million (2021-2026)
  • Table 131. Viral Vector Manufacturing Others , by Region USD Million (2021-2026)
  • Table 132. South America Viral Vector Manufacturing, by Country USD Million (2021-2026)
  • Table 133. South America Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 134. South America Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 135. South America Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 136. Brazil Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 137. Brazil Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 138. Brazil Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 139. Argentina Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 140. Argentina Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 141. Argentina Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 142. Rest of South America Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 143. Rest of South America Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 144. Rest of South America Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 145. Asia Pacific Viral Vector Manufacturing, by Country USD Million (2021-2026)
  • Table 146. Asia Pacific Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 147. Asia Pacific Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 148. Asia Pacific Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 149. China Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 150. China Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 151. China Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 152. Japan Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 153. Japan Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 154. Japan Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 155. India Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 156. India Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 157. India Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 158. South Korea Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 159. South Korea Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 160. South Korea Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 161. Taiwan Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 162. Taiwan Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 163. Taiwan Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 164. Australia Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 165. Australia Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 166. Australia Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 170. Europe Viral Vector Manufacturing, by Country USD Million (2021-2026)
  • Table 171. Europe Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 172. Europe Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 173. Europe Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 174. Germany Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 175. Germany Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 176. Germany Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 177. France Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 178. France Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 179. France Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 180. Italy Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 181. Italy Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 182. Italy Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 183. United Kingdom Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 184. United Kingdom Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 185. United Kingdom Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 186. Netherlands Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 187. Netherlands Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 188. Netherlands Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 189. Rest of Europe Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 190. Rest of Europe Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 191. Rest of Europe Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 192. MEA Viral Vector Manufacturing, by Country USD Million (2021-2026)
  • Table 193. MEA Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 194. MEA Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 195. MEA Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 196. Middle East Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 197. Middle East Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 198. Middle East Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 199. Africa Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 200. Africa Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 201. Africa Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 202. North America Viral Vector Manufacturing, by Country USD Million (2021-2026)
  • Table 203. North America Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 204. North America Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 205. North America Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 206. United States Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 207. United States Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 208. United States Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 209. Canada Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 210. Canada Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 211. Canada Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 212. Mexico Viral Vector Manufacturing, by Type USD Million (2021-2026)
  • Table 213. Mexico Viral Vector Manufacturing, by Application USD Million (2021-2026)
  • Table 214. Mexico Viral Vector Manufacturing, by End User USD Million (2021-2026)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Vector Manufacturing: by Type USD Million (2015-2020)
  • Figure 5. Global Viral Vector Manufacturing: by Application USD Million (2015-2020)
  • Figure 6. Global Viral Vector Manufacturing: by End User USD Million (2015-2020)
  • Figure 7. South America Viral Vector Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Viral Vector Manufacturing Share (%), by Country
  • Figure 9. Europe Viral Vector Manufacturing Share (%), by Country
  • Figure 10. MEA Viral Vector Manufacturing Share (%), by Country
  • Figure 11. North America Viral Vector Manufacturing Share (%), by Country
  • Figure 12. Global Viral Vector Manufacturing share by Players 2020 (%)
  • Figure 13. Global Viral Vector Manufacturing share by Players (Top 3) 2020(%)
  • Figure 14. Global Viral Vector Manufacturing share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 18. Vibalogics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Vibalogics (United States) Revenue: by Geography 2020
  • Figure 20. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 22. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck (Germany) Revenue: by Geography 2020
  • Figure 24. UniQure (Netherlands) Revenue, Net Income and Gross profit
  • Figure 25. UniQure (Netherlands) Revenue: by Geography 2020
  • Figure 26. FUJIFILM Diosynth Biotechnologies (United States) Revenue, Net Income and Gross profit
  • Figure 27. FUJIFILM Diosynth Biotechnologies (United States) Revenue: by Geography 2020
  • Figure 28. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Spark Therapeutics (United States) Revenue: by Geography 2020
  • Figure 30. Oxford BioMedica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Oxford BioMedica (United Kingdom) Revenue: by Geography 2020
  • Figure 32. CGT Catapult (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. CGT Catapult (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Cobra Biologics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Cobra Biologics (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Global Viral Vector Manufacturing: by Type USD Million (2021-2026)
  • Figure 37. Global Viral Vector Manufacturing: by Application USD Million (2021-2026)
  • Figure 38. Global Viral Vector Manufacturing: by End User USD Million (2021-2026)
  • Figure 39. South America Viral Vector Manufacturing Share (%), by Country
  • Figure 40. Asia Pacific Viral Vector Manufacturing Share (%), by Country
  • Figure 41. Europe Viral Vector Manufacturing Share (%), by Country
  • Figure 42. MEA Viral Vector Manufacturing Share (%), by Country
  • Figure 43. North America Viral Vector Manufacturing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Vibalogics (United States)
  • Lonza (Switzerland)
  • Merck (Germany)
  • uniQure (Netherlands)
  • FUJIFILM Diosynth Biotechnologies (United States)
  • Spark Therapeutics (United States)
  • Oxford BioMedica (United Kingdom)
  • CGT Catapult (United Kingdom)
  • Cobra Biologics (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation